Algenics

ALGENICS invited to speak at Gen2Bio, March 29, 2012

algenics — Mon, 20 Feb 2012 10:34:04 +0000

Saint-Herblain (France) – February 20, 2012 - Algenics announced that it will be presenting at Gen2Bio event to be held in Lorient (France), March 29, 2012.

ALGENICS to participate at BIO-Europe Spring, March 19-21, 2012

algenics — Mon, 30 Jan 2012 10:34:16 +0000

Saint-Herblain (France) – January 30, 2012 - Algenics announced that it will be participating at BIO-Europe Spring event to be held in Amsterdam (The Netherlands), March 19-21, 2012.

ALGENICS receives grant to support development of its microalgal protein expression technology for the production of monoclonal antibodies in oncology

algenics — Mon, 30 Jan 2012 10:20:59 +0000

Saint-Herblain (FRANCE) – January 30, 2012 - Algenics, the biopharmaceutical company offering a unique microalgae-based solution for the development of recombinant biotherapeutics, announced that it has received a grant from OSEO, the French innovation agency, with the support of the European Regional Development Fund.

This grant, which is part of a €700 000 phase 1 project, will help support the establishment of an alternative and robust technology for manufacturing of monoclonal antibodies. The ongoing program aims at producing a biobetter of an antibody that has been successfully used in the treatment of various cancers. This second generation biotherapeutic will benefit from features of the microalgal cell line PTA to achieve enhanced biological properties while ensuring compliance with upstream & downstream processes suitable for secreted products into chemically-defined culture medium.

“This grant is fully in line with our strategy to extend our technology to therapeutic areas where we believe it can bring competitive advantage. This R&D program represents an important milestone for Algenics as it will both address the major market of monoclonal antibodies and will initiate the development of a product candidate” said Aude Carlier, CEO & CSO of Algenics.

About ALGENICS:

Algenics S.A.S is a privately-held biopharmaceutical company founded in 2008 and operating its own facility in Saint-Herblain /Nantes (FRANCE).

The company develops recombinant therapeutics for human health by leveraging a unique microalgae-based technology. Our platform Algebiosys^TM encompasses tools to efficiently generate stable strains of microalgal cells with high-level of safety. This proprietary and patented platform allows the biomanufacturing of a broad range of therapeutics including complex multimeric glycoproteins.

Our strategy is to develop biotherapeutics that benefit from our technologies. Our targets include recombinant products with enhanced biological activities for application in oncology and virology.

For more information please visit our website:
www.algenics.com

Contact
Alexandre Lejeune
Business Development Manager
Algenics, Pôle Bio Ouest, rue du Moulin Rousselière
44800 Saint-Herblain, France
T: +33 2 40 40 75 22 • F: +33 2 40 59 32 44

DOWNLOAD THE PDF FILE / TELECHARGER LE FICHIER PDF

ALGENICS to participate at B4B-Connection BIOPRODUCTION event, February 8-9, 2012

algenics — Thu, 05 Jan 2012 14:04:33 +0000

Saint-Herblain (France) – January 05, 2012. Algenics announced that it will be participating at the B4B-Connection BIOPRODUCTION event to be held in Evry Genopole® (France), February 8-9, 2012.

ALGENICS invited to speak at EABA Algae Biomass Conference and Expo, November 29-30, 2011

algenics — Thu, 10 Nov 2011 10:32:53 +0000

Saint-Herblain (France) – November 10 , 2011 - Algenics announced that it will be presenting at the EABA Algae Biomass Conference & Expo to be held in Brussels (Belgium), November 29-30, 2011.

ALGENICS announces €150 000 Participative Priming Loan from OSEO

admin — Thu, 22 Sep 2011 16:00:53 +0000

Saint-Herblain (FRANCE) – September 22, 2011 - Algenics, the biopharmaceutical company offering a unique microalgae-based solution for the development of recombinant biotherapeutics, announced that it has obtained a €150 000 Participative Priming Loan (“Prêt Participatif d’Amorçage”) granted by OSEO, the French innovation agency, with the support of Région Pays de la Loire.

“Through this loan dedicated to innovative SMEs, we are pleased with the renewed support of OSEO. It will help strengthen the company’s R&D efforts and will create favourable conditions for the opening of the capital to future investors” explained Aude Carlier, CEO & CSO of Algenics.

About ALGENICS:

Algenics S.A.S is a privately-held biopharmaceutical company founded in 2008 and operating its own facility in Saint-Herblain /Nantes (FRANCE).

Our strategy is to develop biotherapeutics that benefit from our technologies. Our targets include recombinant products with enhanced biological activities for application in oncology and virology.

For more information please visit our website:
www.algenics.com

Contact
Alexandre Lejeune
Business Development Manager
Algenics, Pôle Bio Ouest, rue du Moulin Rousselière
44800 Saint-Herblain, France
T: +33 2 40 40 75 22 • F: +33 2 40 59 32 44

DOWNLOAD THE PDF FILE / TELECHARGER LE FICHIER PDF

The September 15, 2011, issue of the French magazine “Usine Nouvelle” features an article on Algenics

admin — Thu, 22 Sep 2011 15:26:21 +0000

Read the full article

ALGENICS and NOVIMMUNE announce a research collaboration to express fully human antibodies using the microalgal PTA cell line

algenics — Fri, 17 Jun 2011 13:25:48 +0000

Saint-Herblain (France) Plan-les-Ouates (Switzerland) – June 17, 2011.

Algenics announced a new research collaboration with NovImmune to biomanufacture monoclonal therapeutic antibodies using its proprietary expression platform Algebiosys^TM. Two fully human therapeutic antibodies have been retained from NovImmune’s current pipeline to be produced in the PTA microalgal cell line. There are numerous benefits to using microalgal expression systems over current technologies such as advantageous N-glycosylation profile, natural cell robustness and lack of animal-derived components, while retaining the use of conventional upstream and downstream processing equipments. This collaboration with NovImmune will validate this new and innovative system for the biomanufacturing of fully human therapeutic monoclonal antibodies. Terms around the collaboration have not been disclosed.

“We are delighted to enter this collaboration with NovImmune, a highly innovative company in the field of therapeutic antibodies. This partnership will give us the opportunity to harness the potential of our PTA cell line by comparing products obtained in microalgae with NovImmune’s clinical-stage antibodies” concluded Aude Carlier, CEO & CSO of Algenics.

“NovImmune is pleased to have initiated this collaboration with Algenics for the validation of a new and already promising approach for the expression of monoclonal antibodies”, commented Nicolas Fischer, Head of Research at NovImmune.

About NOVIMMUNE:

NovImmune SA (‘NovImmune’) is a drug discovery and development company with a focus on therapeutic monoclonal antibodies (mAbs) for inflammatory diseases and immune-related disorders. NovImmune has generated, to date, seven proprietary mAbs one of which was licensed to Genentech/Roche. The pipeline is a balance of preclinical and clinical compounds with a mix of both clinically validated as well as novel targets. Each product has the potential to become a medicine for multiple conditions due to the overlapping mechanism of action under laying diseases. Three compounds are in clinical development with the most advanced in Phase II.

For more information please visit our website:
www.novimmune.com

Contact
Luca Bolliger
Director, Business Development and Communication
NovImmune SA • 14 ch. des Aulx • 1228 Plan-Les-Ouates, Geneva • Switzerland
T +41 22 593 51 15 F +41 22 839 71 43

About ALGENICS:

Algenics S.A.S is a privately-held biotechnology company founded in 2008. The company operates its own facility in Saint-Herblain/Nantes (France).
Algenics focuses on innovative uses of microalgae to produce recombinant biotherapeutics. Our technological platform Algebiosys^TM encompasses tools and technologies to efficiently generate stable strains of highly-productive microalgal cells. This proprietary and patented platform allows the biomanufacturing of a broad range of therapeutics in our PTA cell line including complex multimeric glycoproteins.
Our strategy is to identify and produce biotherapeutics that benefit from our technology at the level of industrial proof of concept. Current targets include secreted antibodies and viral envelope immunogens.

For more information please visit our website:
www.algenics.com

Contact
Alexandre Lejeune
Business Development Manager
Algenics, Pôle Bio Ouest, rue du Moulin Rousselière
44800 Saint-Herblain, France
T: +33 2 40 40 75 22 • F: +33 2 40 59 32 44

DOWNLOAD THE PDF FILE

ALGENICS to participate at Biomarine International Business Convention, September 7-9, 2011

algenics — Thu, 16 Jun 2011 14:25:14 +0000

Saint-Herblain (France) – June 16, 2011. Algenics announced that it will be participating at the Biomarine International Business Convention to be held in Nantes & Saint-Nazaire (France), September 7-9, 2011.